english.prescrire.org

Welcome to the Prescrire in English website

Reliable, rigorously independent information on treatments and healthcare strategies,
to enable fully informed decision-making. Prescrire is financed by its subscribers.
No grants, no advertising. No shareholders, no sponsors.

In Prescrire's Spotlight

Psychotic episode: which oral neuroleptic to choose? A choice tailored to each patient, based on the adverse effect profiles of the options

1 July 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
In the July-August issue of Prescrire International: emtricitabine + tenofovir disoproxil (Truvada° and other brands) for prevention of HIV infection in adolescents

1 July 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Fentanyl (Actiq° and other brands) and other opioids: risk of increased pain

1 July 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
A clear example of marketing's influence on prescribers

1 July 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Prescrire's packaging review for 2018: ways to reduce dangers

1 July 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Prescrire's response to the EMA Regulatory Science strategy to 2025: refocus on public health mission as gatekeeper and strengthen pharmacovigilance

1 August 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Enjoy these features, and more, in our upcoming issues

1 July 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Subscribe today for full access to top-quality content from Prescrire International

1 December 2018

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
"Top Texts of 2018", from the Editors of Prescrire International

1 October 2018

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Receive the free, monthly "Independent Drug & Healthcare Newsletter"

1 September 2018